Biotechnology is also a vital engine of economic prosperity, generating almost 7% of U.S. private-sector GDP and supporting roughly 10 million jobs across all 50 states. The good news is that we still ...

The team at GV manages some $10 billion that the tech giant has set aside for early-stage companies. Schenkein’s group ...

Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway ...

MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA”, the 'Company”), a clinical-stage biopharmaceutical company focused on ...

Future tech 2030 will reshape daily life with AI, quantum computing, autonomous vehicles, and more. Stay ahead with top tech ...

During the upscaling process, Polyrizon and its manufacturing partner successfully transitioned from small-batch laboratory production to a larger-scale, controlled manufacturing run designed to ...

Capital has become discerning. The inflated valuations of 2021 have given way to a more disciplined environment where ...

Nainital: Uttarakhand Council for Biotechnology (UCB), in collaboration with Graphic Era Hill University, Dehradun, and MIET ...

The prospect of diagnosing cancer through painless methods—such as a simple AI-assisted blood or urine test that detects tiny ...

The SBIO ETF has staged a remarkable comeback, outperforming despite a challenging macro backdrop and small-cap weakness.

Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

The Republic may not have a major player to call its own, but licensing deals and early-stage breakthroughs can still count ...